We previously showed that co-targeting HH/GLI (GLI1/2 inhibitor GANT-61, SMO inhibitor MRT-92) and MEK5/ERK5 (ERK5 inhibitor XMD8-92 or JWG-071, MEK5 inhibitor BIX02189) pathways elicits significant antitumor activity in melanoma cells, including a drastic reduction of melanoma cell proliferation and colony formation ability [14]. Here, SMO is linked to melanoma.